✦ LIBER ✦

PCN87 PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT

✍ Scribed by A Tikhomirova; A Kulikov; R Yagudina

Book ID: 118614177
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 79 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)71982-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN91 Pharmacoeconomic Analysis of mCRC

PCN91 Pharmacoeconomic Analysis of mCRC Therapy With XELOX/FOLFOX4 Regimes With Bevacizumab or Cetuximab as the First Line Treatment in Russia

✍ Tikhomirova, A.V.; Yagudina, R.I.; Kulikov, A.U. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN26 A COST-EFFECTIVENESS ANALYSIS OF X

PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

✍ J Darba; G Restovic; A Ramírez de Arellano 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Pharmaco-economic analysis of direct med

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia

✍ Tran, Giao; Hack, Stephen P; Kerr, Annette; Stokes, Leanne; Gibbs, Peter; Price, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB

Safety and Efficacy of Oxaliplatin and F

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

✍ Hochster, H. S.; Hart, L. L.; Ramanathan, R. K.; Childs, B. H.; Hainsworth, J. D 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 149 KB

The cost effectiveness of bevacizumab wh

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study

✍ Carter, Hannah E.; Zannino, Diana; John Simes, R.; Schofield, Deborah J.; Howard 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 773 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB